文献速递间质性肺疾病

希腊-土耳其-塞浦路斯肺泡蛋白沉积症真实世界比较研究

Pulmonary Alveolar Proteinosis in Greece-Türkiye-Cyprus: Answers in a Real-Life Comparison.
PubMed 文献 · Respirology · 2026-07-15

在86例可分析自身免疫性PAP患者中,单独吸入GM-CSF治疗与全肺灌洗或联合治疗相比未显示结局差异,而肺纤维化负向影响治疗反应和生存。

要点

  • 自身免疫性PAP占89%,中位诊断年龄40岁,中位随访39个月。
  • 单独吸入GM-CSF与全肺灌洗或联合治疗相比,死亡/存活无显著差异。
  • 肺纤维化消除所有治疗组的获益反应,并与非存活者更高心血管病和LTOT率相关。

核心结论

  • 首次三国真实世界比较显示,单独吸入GM-CSF治疗自身免疫性PAP非劣于全肺灌洗或联合治疗。
  • 肺纤维化负向影响治疗反应和生存。

研究设计与样本

  • 回顾性图表审查研究,比较希腊、土耳其、塞浦路斯三个队列,随访20年。
  • 115例(89%)为自身免疫性PAP,13例(10%)继发性,1例(1%)遗传性。
  • 86/115例自身免疫性PAP患者有异常抗GM-CSF抗体滴度数据并进一步分析。

主要发现

  • 自身免疫性PAP分析人群中,40例(46%)为男性,中位(IQR)诊断年龄40(31-50)岁。
  • 中位(IQR)临床随访时间39(18-78)个月,3例患者死亡。
  • 非存活者心血管疾病发生率67% vs. 5%(p < 0.001),LTOT使用率67% vs. 13%(p = 0.001),肺纤维化发生率67% vs. 5%。
  • 随访时非存活者功能状态更差:FVC% pred 49(29)vs. 87(74-97),p = 0.026;DLCO% pred 21(46)vs. 72(58-82),p = 0.016。
  • 土耳其更常进行全肺灌洗,希腊更常单独使用吸入GM-CSF(p = 0.006);单独吸入GM-CSF与全肺灌洗或联合治疗相比,死亡/存活0%/100% vs. 7%/93%(p = 0.491)。

关键数值与推荐

  • 单独吸入GM-CSF显著改善疾病严重程度临床和功能参数:DLCO% pred(p = 0.013)、SatO2(p = 0.002)、6MWT(p = 0.026)。
  • 所有治疗均有效,但跨所有治疗组,肺纤维化消除对治疗的有利反应。

临床怎么用

  • 对于自身免疫性PAP,单独吸入GM-CSF可作为全肺灌洗或联合治疗的替代选择。
  • 评估PAP患者时应关注肺纤维化,其提示治疗反应和生存较差。

局限性

  • 回顾性图表审查设计。
  • 仅86/115例自身免疫性PAP患者有抗GM-CSF抗体滴度数据。
  • 样本量有限且三国队列人数不均衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Pulmonary alveolar proteinosis (PAP) is a rare disease of inappropriate alveolar surfactant accumulation. The study objective was to compare Greece-Türkiye-Cyprus cohorts, followed-up for 20 years. METHODS: Data were retrieved retrospectively by chart review. RESULTS: One hundred and thirty patients, Greece 39, Türkiye 87, Cyprus 4, were included; 115 (89%) autoimmune (a)PAP, 13 (10%) secondary, 1 (1%) hereditary. Abnormal anti-GM-CSF antibody titre was available in 86/115 patients, further analyzed for aPAP. Forty (46%) were male, with median (IQR) age at diagnosis of 40 (31-50) years. At median (IQR) duration of clinical follow-up of 39 (18-78) months, three patients died. Non-survivors had higher rates of cardiovascular disease [67% vs. 5%, p < 0.001], LTOT (67% vs. 13%, p = 0.001), pulmonary fibrosis [67% vs. 5%] and worse functional status at follow-up [FVC% pred 49 (29) vs. 87 (74-97); p = 0.026, DLCO% pred 21 (46) vs. 72 (58-82); p = 0.016]. aPAP patients were stratified by therapy group (no WLL-no i-GM-CSF, WLL alone, i-GMCSF alone and both WLL and iGM-CSF). WLL was more frequently performed in Türkiye and i-GMCSF alone in Greece (p = 0.006). All therapies were effective. No difference was detected on outcome when sole iGM-CSF was compared to WLL alone or in combination with iGM-CSF [deceased/alive 0%/100% vs. 7%/93%, p = 0.491]. Sole iGM-CSF significantly ameliorated clinical and functional parameters of disease severity [DLCO% (p = 0.013), SatO2 (p = 0.002), 6MWT (p = 0.026)]. Across all therapy groups, pulmonary fibrosis eliminated beneficial response to treatment. CONCLUSION: This first real-life comparison of aPAP cohorts originating from three countries showed the non-inferiority of sole iGM-CSF treatment. Fibrosis negatively affects response to treatment and survival.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Papiris SA, Chousein EGU, Kallieri M, et al. Pulmonary Alveolar Proteinosis in Greece-Türkiye-Cyprus: Answers in a Real-Life Comparison. Respirology. 2026. PMID: 42457194. doi:10.1002/resp.70288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。